scientifyRESEARCH
research funding database

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

RESEARCH FUNDING

Kidney Cancer Research Program: Concept Award (worldwide)

Share

Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange plus symbol appears between the two logos.
Text on a blue background says "Want to find funding & get support for grant-writing?" Logos of scientifyRESEARCH & GrantDesk appear below on a white background and an orange play symbol appears between the two logos. An arrow mark points to the logos.

The Kidney Cancer Research Program: Concept Award from the Congressionally Directed Medical Research Programs (CDMRP) supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. The program is open to researchers in the USA and worldwide, including academic institutions and biotechnology companies. The award provides up to 100,000 USD over 1 year. Indirect costs may be covered.

Funding Opportunity Number: HT9425-23-KCRP-CA

Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), July 20, 2023. Application Submission Deadline: 11:59 p.m. ET, August 3, 2023.

Full application due:
August 3, 2023

non member

More related info for you

Register for free

Don´t have an account?

Start with our free trial to enjoy our 7 days of unlimited grant access and our premium features.

or, Choose a plan to subscribe to our premium membership.

Be the first to know

Sign-up for Personalized Grant alerts

Logo3

Sign-up for our
monthly research
funding newsletter

You can unsubscribe at any time.